Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 159

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes and Moderate-to-Severe Chronic Renal Insufficiency

Open access
Arjona Ferreira, Juan Camilo, Marre, Michel, Barzilai, Nir, Guo, Hua, Golm, Gregory T., Sisk, Christine McCrary, Kaufman, Keith D., Goldstein, Barry J. · 2013 · Diabetes Care

Abstract

OBJECTIVE: Patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease have an increased risk of micro- and macrovascular disease, but limited options for antihyperglycemic therapy. We compared the efficacy and safety of sitagliptin with glipizide in patients with T2DM and moderate-to-severe chronic renal insufficiency and inadequate glycemic control. RESEARCH DESIGN AND METHODS: Patients (n = 426) were randomized 1:1 to sitagliptin (50 mg every day [q.d.] for moderate renal insufficiency and 25 mg q.d. for severe renal insufficiency) or glipizide (2.5 mg q.d., adjusted based on glycemic control to a 10-mg twice a day maximum dose). Randomization was stratified by: 1) renal status (moderate or severe renal insufficiency); 2) history of cardiovascular disease; and 3) history of heart failure. RESULTS: At week 54, treatment with sitagliptin was noninferior to treatment with glipizide in A1C change from baseline (−0.8 vs. −0.6%; between-group difference −0.11%; 95% CI −0.29 to 0.06) because the upper bound of the 95% CI was less than the prespecified noninferiority margin of 0.4%. There was a lower incidence of symptomatic hypoglycemia adverse events (AEs) with sitagliptin versus glipizide (6.2 and 17.0%, respectively; P = 0.001) and a decrease in body weight with sitagliptin (−0.6 kg) versus an increase (1.2 kg) with glipizide (difference, −1.8 kg; P < 0.001). The incidence of gastrointestinal AEs was low with both treatments. CONCLUSIONS: In patients with T2DM and chronic renal insufficiency, sitagliptin and glipizide provided similar A1C-lowering efficacy. Sitagliptin was generally well-tolerated, with a lower risk of hypoglycemia and weight loss versus weight gain, relative to glipizide.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc12-1365

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 16

  1. United States Renal Data System, 2010, 2010 Annual Data Report (Volume 1): Atlas of Chronic Kidney Disease in the United States
  2. Inzucchi, 2002, Oral antihyperglycemic therapy for type 2 diabetes: scientific review, JAMA, 287, 360, 10.1001/jama.287.3.360 · DOI · Paper page
  3. Odegard, 2007, Considerations for the pharmacological treatment of diabetes in older adults, Diabetes Spectrum, 20, 239, 10.2337/diaspect.20.4.239 · DOI
  4. Davis, 2010, Determinants of severe hypoglycemia complicating type 2 diabetes: the Fremantle diabetes study, J Clin Endocrinol Metab, 95, 2240, 10.1210/jc.2009-2828 · DOI · Paper page
  5. Krepinsky, 2000, Prolonged sulfonylurea-induced hypoglycemia in diabetic patients with end-stage renal disease, Am J Kidney Dis, 35, 500, 10.1016/S0272-6386(00)70204-6 · DOI
  6. Herman, 2006, Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes, J Clin Endocrinol Metab, 91, 4612, 10.1210/jc.2006-1009 · DOI · Paper page
  7. Kim, 2005, (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes, J Med Chem, 48, 141, 10.1021/jm0493156 · DOI · Paper page
  8. Nauck, 2007, Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial, Diabetes Obes Metab, 9, 194, 10.1111/j.1463-1326.2006.00704.x · DOI · Paper page
  9. Herman, 2005, Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses, Clin Pharmacol Ther, 78, 675, 10.1016/j.clpt.2005.09.002 · DOI · Paper page
  10. Bergman, 2006, Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers, Clin Ther, 28, 55, 10.1016/j.clinthera.2006.01.015 · DOI · Paper page
  11. Chan, 2008, Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency, Diabetes Obes Metab, 10, 545, 10.1111/j.1463-1326.2008.00914.x · DOI · Paper page
  12. Tura, 2003, Basal and dynamic proinsulin-insulin relationship to assess beta-cell function during OGTT in metabolic disorders, Am J Physiol Endocrinol Metab, 285, E155, 10.1152/ajpendo.00104.2002 · DOI
  13. Street, 1988, A note on computing robust regression estimates via iteratively reweighted least squares, Am Stat, 42, 152, 10.1080/00031305.1988.10475548 · DOI · Paper page
  14. Miettinen, 1985, Comparative analysis of two rates, Stat Med, 4, 213, 10.1002/sim.4780040211 · DOI · Paper page
  15. Aschner, 2006, Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes, Diabetes Care, 29, 2632, 10.2337/dc06-0703 · DOI · Paper page
  16. Raz, 2006, Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus, Diabetologia, 49, 2564, 10.1007/s00125-006-0416-z · DOI · Paper page

Cited by

See all 159

Metadata

Authors
Arjona Ferreira, J. C., Marre, M., Barzilai, N., Guo, H., Golm, G. T., Sisk, C. M., Kaufman, K. D., & Goldstein, B. J.
Venue
Diabetes Care
Published
2013-04-13
Volume
36
Issue
5
Pages
1067-1073
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2121162069
Cited by
159
References
5
FWCI
13.81
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.